Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ SMURF2 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA581262
Description
This product is preservative free. It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%). This antibody has specificity for Human SMURF2.
SMURF2 is an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. This protein interacts with SMAD1, SMAD2 and SMAD7 in order to trigger their ubiquitination and proteasome-dependent degradation. It enhances the inhibitory activity of SMAD7 and reduces the transcriptional activity of SMAD2. Coexpression of SMURF2 with SMAD1 results in considerable decrease in steady-state level of SMAD1 protein and a smaller decrease of SMAD2 level.
Specifications
SMURF2 | |
Polyclonal | |
Unconjugated | |
Smurf2 | |
2810411E22Rik; AI558114; AI649275; E3 ubiquitin ligase SMURF2; E3 ubiquitin-protein ligase SMURF2; HECT-type E3 ubiquitin transferase SMURF2; hSMURF2; RGD1310067; SMAD specific E3 ubiquitin protein ligase 2; SMAD ubiquitination regulatory factor 2; SMAD-specific E3 ubiquitin-protein ligase 2; SMURF2 | |
Rabbit | |
Antigen affinity chromatography, Protein A | |
RUO | |
64750 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry | |
5 mg/mL | |
PBS with no preservative | |
Q9HAU4 | |
Smurf2 | |
A synthetic peptide corresponding to the N-terminus of the Human SMURF2. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction